BPIQ Blog

Mar 22, 20232 min read

ETNB Phase 2b Data Reported!!

Summary: Phase 2b ETNB ENLIVEN data was reported today (3/22/23) & trial met primary endpoints How does this data compare to previous...

Mar 21, 20232 min read

3 Mental Health Readouts Left as March Movers!

Summary: ITCI, NRXP & VTGN are left in our March Movers list, all are in the mental health category NRXP & VTGN are March Big Movers and...

Mar 20, 20232 min read

IONS & BIIB Tofersen AdComm on Wednesday!

Summary: The IONS and BIIB AdComm meeting for Tofersen is scheduled for this Wednesday, March 22! Briefing docs were released today...

Mar 17, 20231 min read

Biopharma Pulse - 3/13 - 3/17 Weekly Review

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Mar 17, 20231 min read

Biotech Q1 '23 Catalyst Countdown

We're coming down to the final weeks of Q1 2023. This past week XBI finished green up ~1%, although it still sits in the mid $70's. See...

Mar 16, 20233 min read

CDTX's Rezafungin PDUFA Coming Soon!

Summary: The CDTX PDUFA for Rezafungin to treat candidemia and invasive candidiasis is scheduled for March 22 Positive Phase 3 data from...

Mar 15, 20232 min read

Over 20 Smid-Cap Biopharmas Presenting at AACR 2023!

Summary: The American Association for Cancer Research (AACR) 2023 Annual Meeting will take place from April 14-19, 2023, abstracts...

Mar 12, 20231 min read

Biotech Catalyst Watchlist Q1 2023 Part 2

Each week we're posting a countdown of the remaining catalysts left in Q1! Last week was a rough week for biotech's with XBI finishing...

Mar 10, 20231 min read

Biopharma Pulse - 3/6 - 3/10 Weekly Review

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Mar 7, 20232 min read

ACAD's Trofinetide PDUFA Coming Sunday

Summary: The ACAD Trofinetide PDUFA is expected this Sunday March 12, 2023 Will we see an early decision before the weekend? See our full...

Mar 6, 20233 min read

ESPR CLEAR Outcomes Data Finally Here!

First published 3/6/23 - currently in progress Summary: ESPR CLEAR outcomes data from NEXLETOL trial reported over the weekend at ACC.23...

Mar 5, 20231 min read

Weekly Biotech Catalyst Watchlist Q1 2023

Last week was a green week for XBI (biotech ETF), which finished the week up +2.3%, see the biggest news from last week, including a full...

Mar 3, 20231 min read

Biopharma Pulse - 2/27-3/3 Weekly Review

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Mar 2, 20232 min read

Available Oncology Investor Conference Webcasts

Summary: Several recent oncology investor conferences are still available to the public, including all company webcasts These conferences...

Mar 1, 20231 min read

10 Rare Disease Catalysts to Watch

First posted 3/10/2023; last updated 5/1/2023 Summary: Many exciting rare diseases catalysts are coming throughout the year See the table...

Feb 25, 20231 min read

Weekly Biotech Catalyst Watchlist Feb/March

Last week was a tough week for biotech, XBI (biotech ETF) saw a 6% pullback, see the biggest news from last week, including a full table...

Feb 24, 20231 min read

Biopharma Pulse - 2/20-2/24 Weekly Review

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Feb 22, 20234 min read

Reata Pharmaceuticals (RETA) Concerns For Upcoming PDUFA Decision

Summary: Reata Pharmaceuticals has a PDUFA data for Omaveloxolone for FA 2/28/23. The previous PDUFA date was extended 3 months after...

Feb 22, 20233 min read

Upcoming Pegozafermin NASH Readout!

Summary: The upcoming readout from ETNB includes Phase 2b data from the pegozafermin trial in NASH. This is a Suspected Mover for Q1...

Feb 21, 20231 min read

Blood Cancer & Disease Biotech Stock Catalyst Watchlist

Last updated 4/11/23 Summary: Many exciting blood cancer & disease catalysts are coming throughout the year See the table below for some...

Jump start your biotech due diligence

Get started →

Our platform helps you uncover your next biotech investment opportunity